The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: demyelinating following therapy with an immune checkpoint inhibitor
Demyelinating disease includes:
(1) multiple sclerosis
(2) transverse myelitis
(3) acute disseminated encephalomyelitis (ADEM)
(4) optic neuritis (ON)
(5) neuromyelitis optica (NMO)
Parameters:
(1) signs and symptoms
(2) activities of daily living
|
Signs and Symptoms
|
Activities of Daily Living
|
Grade
|
|
none or mild
|
normal
|
G1
|
|
moderate
|
affects age-appropriate instrumental ADL
|
G2
|
|
severe. medically significant
|
affects self-care ADL
|
G3
|
|
life-threatening
|
NA
|
G4
|
The diagnosis requires exclusion of other causes for the demyelination.
